Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05361798CT.gov A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy | — | Recruiting | — | — | — |
NCT04633252CT.gov A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| pds01adc (this asset) | National Cancer Institute (NCI) | P2 | B · 60 |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Degarelix | Baptist Health South Florida | P3 | BBB |
| Prednisone | Mayo Clinic | P4 | BBB |
| Enzalutamide | Pfizer | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BBB |
| Docetaxel | Alliance for Clinical Trials in Oncology | P3 | BB |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P2/3 | BB |
| Goserelin | Mayo Clinic | P3 | BB |
+42 more in the Prostate Carcinoma cohort
Other indications for pds01adc
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 53 |
| Intrahepatic Bile Duct Cancer | — | P2 | CCC · 53 |
| Bile Duct Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. pds01adc in Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pds01adc-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →